HK Stock Market Move | GENFLEET-B(02595) closed up more than 8% with GFH375 starting Phase III clinical trial for metastatic pancreatic cancer.

GENFLEET-B(02595) closes up over 8%, as of the press release, up 7.46%, at HK$31.1, with a turnover of HK$280.849 million. On the news front, on November 11th, the Drug Clinical Trial Registration and Information Disclosure Platform showed that Jinfang Medicine has initiated a multicenter, open-label, randomized Phase III clinical study to evaluate the effectiveness and safety/tolerability of GFH375 monotherapy compared to investigator-choice chemotherapy in the treatment of patients with KRAS G12D mutant advanced pancreatic cancer. According to the company's prospectus, GFH375 is developed as a first-line G12D inhibitor for oral administration. This product's monotherapy was approved for Phase I/II trials in June 2024. GFH375/VS-7375 has already obtained FDA Fast Track designation this year and can be used for frontline and salvage therapy for local advanced and metastatic KRAS G12D mutant PDAC patients. Previously, early data from GFH375 monotherapy in solid tumors was disclosed at prestigious international academic conferences such as ASCO and WCLC this year through LBA and oral presentations.